Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR-Reference-Cited by-同舟云学术

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Published:2010-06-24 Issue:25 Volume:362 Page:2380-2388
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Maemondo Makoto,Inoue Akira,Kobayashi Kunihiko,Sugawara Shunichi,Oizumi Satoshi,Isobe Hiroshi,Gemma Akihiko,Harada Masao,Yoshizawa Hirohisa,Kinoshita Ichiro,Fujita Yuka,Okinaga Shoji,Hirano Haruto,Yoshimori Kozo,Harada Toshiyuki,Ogura Takashi,Ando Masahiro,Miyazawa Hitoshi,Tanaka Tomoaki,Saijo Yasuo,Hagiwara Koichi,Morita Satoshi,Nukiwa Toshihiro

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa0909530

Cited by 4828 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer;Translational Oncology;2024-11

2. Naringin alleviates gefitinib-induced hepatotoxicity through anti-oxidation, inhibition of apoptosis, and autophagy;IRAN J BASIC MED SCI;2024

3. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

4. Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study;Frontiers in Pharmacology;2024-09-06

5. Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with hereditary gastric cancer linked to a family history of hereditary breast and ovarian cancer (HBOC);2024-09-05